The psychedelic renaissance is now at a point of reckoning, and the extraordinary promise of these drugs to quickly and easily transform lives for the better is starting to look more like a fever dream.
Read moreGroup Psychedelic Experiences and Success
Adverse Effects
This research study looks at the adverse effects in studies of psychedelics and MDMA.
Read morePsilocybin for Inner Healing Depression
The journey to healing from depression often demands more than just symptom management; it requires a deep, inner transformation that addresses the root of emotional distress.
This inner healing process is crucial for those suffering from depression, as it can lead to more profound and lasting recovery.
Read moreThree Studies of MDMA Treatment Retracted by Scientific Journal
The journal Psychopharmacology has retracted three papers about MDMA-assisted therapy based on what the publication said was unethical conduct at one of the study sites where the research took place.
Several of the papers’ authors are affiliated with Lykos Therapeutics, the drug company whose application for MDMA-assisted therapy to treat post-traumatic stress disorder was rejected last week by the Food and Drug Administration.
Read moreAnthropology and Psychedelics
Here’s an interview with an anthropologist who studies psychedelics, and what trends she notices so far.
Read morePsilocybin's Effects on the Brain
UC Berkeley’s Groundbreaking Study on Psilocybin
This investigation represents the university’s first human trials involving a Schedule I substance, classified by the federal government as having no accepted medical use.
Psilocybin, commonly known as “shrooms” or “magic mushrooms,” can significantly distort users’ sense of time, mood, and reality, often causing hallucinations.
Read moreAre Animals Conscious?
Cluster Headaches and Psychedelics
Here’s a wonderful article on how people with cluster headaches became unexpected psychedelic pioneers.
Read moreF.D.A. Panel Votes Against MDMA-Assisted Therapy for PTSD
The Food and Drug Administration’s Psychopharmacologic Drugs Advisory Committee voted overwhelmingly to reject MDMA-assisted therapy in the treatment of post traumatic stress disorder, or PTSD.
The FDA will issue its final decision on the matter in mid-August but in the majority of cases, the federal agency’s decisions align with the vote of the independent panelists on advisory committees.
Read more